Holen Sie sich die Stockscreener-App
28.65
3.06%
0.85
Handel nachbörslich:
28.51
-0.14
-0.49%
Schlusskurs vom Vortag:
$27.80
Offen:
$27.5
24-Stunden-Volumen:
1.91M
Relative Volume:
0.82
Marktkapitalisierung:
$3.62B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-14.11
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
+2.14%
1M Leistung:
+18.10%
6M Leistung:
+14.37%
1J Leistung:
-24.17%
1-Tages-Spanne:
$27.26
$28.67
1-Wochen-Bereich:
$27.14
$28.67
52-Wochen-Spanne:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
28.65 | 3.56B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Transcript : Apellis Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 08 - MarketScreener
Can Apellis Pharmaceuticals Inc. deliver alphaJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - khodrobank.com
Analyzing drawdowns of Apellis Pharmaceuticals Inc. with statistical toolsTrend Reversal & Stepwise Swing Trade Plans - Newser
Backtesting results for Apellis Pharmaceuticals Inc. trading strategiesTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Will Apellis Pharmaceuticals Inc. stock benefit from interest rate changesRate Cut & AI Optimized Trading Strategy Guides - Newser
What earnings revisions data tells us about Apellis Pharmaceuticals Inc.July 2025 Action & Weekly Return Optimization Alerts - Newser
Can machine learning forecast Apellis Pharmaceuticals Inc. recoveryMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Apellis Pharma VP Chopas sells $15k in shares - Investing.com
Can trapped investors hope for a rebound in Apellis Pharmaceuticals Inc.Buy Signal & Comprehensive Market Scan Insights - Newser
What’s the MACD signal for Apellis Pharmaceuticals Inc.Trade Risk Assessment & Weekly High Return Forecasts - khodrobank.com
Transcript : Apellis Pharmaceuticals, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
Analyzing net buyer seller activity in Apellis Pharmaceuticals Inc.July 2025 Gainers & Weekly High Conviction Trade Ideas - Newser
Apellis Pharmaceuticals Inc. stock retracement – recovery analysisJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - Newser
What data driven models say about Apellis Pharmaceuticals Inc.’s futureEarnings Miss & Short-Term High Return Strategies - Newser
Published on: 2025-09-03 02:41:06 - Newser
How is Apellis Pharmaceuticals Inc. managing supply chain issuesWeekly Trend Recap & Growth Focused Stock Reports - khodrobank.com
Order flow analysis tools used on Apellis Pharmaceuticals Inc.Watch List & Consistent Growth Equity Picks - Newser
Should value investors consider Apellis Pharmaceuticals Inc.July 2025 News Drivers & Community Consensus Stock Picks - khodrobank.com
What’s the beta of Apellis Pharmaceuticals Inc. stockQuarterly Earnings Summary & Fast Entry Momentum Alerts - khodrobank.com
Key metrics from Apellis Pharmaceuticals Inc.’s quarterly dataJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - Newser
What’s the profit margin of Apellis Pharmaceuticals Inc.Dollar Strength & Real-Time Stock Movement Alerts - khodrobank.com
Is Apellis Set for a Rebound? - timothysykes.com
Is Apellis Pharmaceuticals Inc. stock a value trap2025 Earnings Impact & High Return Trade Guides - khodrobank.com
Will Apellis Pharmaceuticals Inc. stock recover after recent dropRecession Risk & Safe Capital Investment Plans - Newser
Is Apellis Pharmaceuticals Inc. meeting your algorithmic filter criteriaOptions Play & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-01 23:36:26 - Newser
What the charts say about Apellis Pharmaceuticals Inc. today2025 Performance Recap & Entry Point Strategy Guides - Newser
What to do if you’re stuck in Apellis Pharmaceuticals Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
How cyclical is Apellis Pharmaceuticals Inc.’s revenue streamMarket Sentiment Report & Entry and Exit Point Strategies - khodrobank.com
Published on: 2025-09-01 19:43:22 - Newser
Real time social sentiment graph for Apellis Pharmaceuticals Inc.Quarterly Trade Review & Reliable Entry Point Alerts - Newser
Has Apellis Pharmaceuticals Inc. found a price floor2025 Market Outlook & Low Drawdown Momentum Trade Ideas - Newser
Apellis Pharmaceuticals Inc. Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - 강소기업뉴스
Should I hold or sell Apellis Pharmaceuticals Inc. nowExit Point & Breakout Confirmation Trade Signals - khodrobank.com
Is Apellis Pharmaceuticals Inc. reversing from oversold territoryWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
How to track smart money flows in Apellis Pharmaceuticals Inc.July 2025 Trends & Precise Swing Trade Entry Alerts - Newser
Have Insiders Sold Apellis Pharmaceuticals Shares Recently? - simplywall.st
Automated trading signals detected on Apellis Pharmaceuticals Inc.Buy Signal & Safe Capital Investment Plans - Newser
Apellis Pharmaceuticals Inc. stock momentum explained2025 Top Gainers & Smart Allocation Stock Tips - Newser
Using fundamentals and technicals on Apellis Pharmaceuticals Inc.Weekly Trend Summary & Technical Entry and Exit Alerts - Newser
Heatmap analysis for Apellis Pharmaceuticals Inc. and competitorsQuarterly Earnings Summary & Intraday High Probability Setup Alerts - Newser
Can Apellis Pharmaceuticals Inc. recover in the next quarterJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - Newser
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):